United States· US:73362-102_93f0f8d6-548d-4961-bf87-565892563f0e
Yorvipath
A palopegteriparatide product containing palopegteriparatide, registered in United States by Ascendis Pharma, Endocrinology, Inc.. The same ATC class is registered in 11 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Palopegteriparatide is registered in 11 of 19 countries.
Countries holding a registration under ATC H05AA05 (palopegteriparatide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Palopegteriparatide · ATC H05AA05
11 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PALOPEGTERIPARATIDE
- Manufacturer
- Ascendis Pharma, Endocrinology, Inc.
- Country
- United States (US)
- ATC code
- H05AA05
- ATC class
- Palopegteriparatide
- Defined daily dose
- 33 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1173362-102-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palopegteriparatide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsYorvipath 168 microgram/0,56 ml oplossing voor injectie in voorgevulde penAscendis Pharma A/S
- CzechiaYORVIPATHAscendis Pharma Bone Diseases A/S, Hellerup
- SwitzerlandYorvipath 168 μg/0.56 ml, Injektionslösung im FertigpenAscendis Pharma Switzerland GmbH
- BelgiumYorvipath 168 µg/0.56 mlAscendis Pharma Bone Diseases
- United KingdomYorvipath 168micrograms/0.56ml solution for injection pre-filled pensAscendis Pharma UK Ltd
- PolandYorvipathAscendis Pharma Bone Diseases A/S
- SwedenYorvipath 168 mikrogram/0,56 ml Injektionsvätska, lösning i förfylld injektionspennaAscendis Pharma Bone Diseases A/S
- FranceYORVIPATH 168 microgrammes/0,56 mL, solution injectable en stylo prérempliASCENDIS PHARMA BONE DISEASES (DANEMARK)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yorvipath
- Liechtenstein · Yorvipath
- Norway · Yorvipath
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba685ccf-deed-47ba-854f-c5f0cd3aa892 GET /v1/drugs/ba685ccf-deed-47ba-854f-c5f0cd3aa892?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "420",
"substance": "PALOPEGTERIPARATIDE",
"productndc": "73362-102",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "ug/1.4mL",
"application_number": "NDA216490",
"marketing_category": "NDA"
}See everything about palopegteriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.